Edwards Lifesciences Yönetim
Yönetim kriter kontrolleri 3/4
Edwards Lifesciences CEO'su Bernard Zovighian, May2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı $ 12.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.6% maaş ve 92.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.012% ine doğrudan sahiptir ve bu hisseler $ 4.84M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.2 yıl ve 4.5 yıldır.
Anahtar bilgiler
Bernard Zovighian
İcra Kurulu Başkanı
US$12.9m
Toplam tazminat
| CEO maaş yüzdesi | 7.6% |
| CEO görev süresi | 1.5yrs |
| CEO sahipliği | 0.01% |
| Yönetim ortalama görev süresi | 5.2yrs |
| Yönetim Kurulu ortalama görev süresi | 4.5yrs |
Son yönetim güncellemeleri
Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$13m | US$973k | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$1b |
| Dec 31 2022 | US$3m | US$642k | US$2b |
Tazminat ve Piyasa: Bernard 'ın toplam tazminatı ($USD 12.87M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 12.74M ).
Tazminat ve Kazançlar: Bernard 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Bernard Zovighian (56 yo)
1.5yrs
Görev süresi
US$12,869,020
Tazminat
Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$12.87m | 0.012% $ 4.8m | |
| Corporate VP & CFO | 10.8yrs | US$5.95m | 0.046% $ 18.5m | |
| Corporate Vice President of Strategy & Corporate Development | 8.8yrs | US$4.29m | 0.035% $ 14.0m | |
| Corporate VP and Group President of TAVR & Surgical Structural Heart | 1.8yrs | US$5.40m | 0.030% $ 12.1m | |
| Principal Accounting Officer | less than a year | Veri yok | 0.00030% $ 119.9k | |
| Corporate VP of Advanced Technology & Chief Scientific Officer | 5.8yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Corporate VP & General Counsel | 5.2yrs | Veri yok | Veri yok | |
| Corporate Vice President of Public Affairs | 11.4yrs | Veri yok | Veri yok | |
| Corporate Vice President of Human Resources | 12.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Quality & Regulatory Compliance | 1.3yrs | Veri yok | Veri yok | |
| GM & Senior VP of Surgical Structural Heart | 1.3yrs | Veri yok | 0.00021% $ 83.9k |
5.2yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: EW 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$12.87m | 0.012% $ 4.8m | |
| Independent Director | 9.8yrs | US$335.06k | 0.012% $ 4.9m | |
| Independent Director | 4.3yrs | US$329.97k | 0.0013% $ 523.5k | |
| Independent Director | 8.7yrs | US$335.06k | 0.012% $ 4.8m | |
| Independent Director | 8.3yrs | US$356.42k | 0.0046% $ 1.8m | |
| Independent Chairman | 10yrs | US$347.97k | 0.012% $ 4.7m | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Director | less than a year | Veri yok | Veri yok | |
| Independent Director | 4.5yrs | US$334.97k | 0.0019% $ 747.3k |
4.5yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: EW 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).